A Growing Race to Change Status Quo in the Lucrative NGS Market

The new capital will support the expansion of Element Biosciences' global customer base and the advancement of its technological offerings. Central to these efforts is the AVITI™ benchtop DNA sequencer, which has been rapidly adopted since its release. Additionally, the company plans to launch AVITI24™, an instrument designed to integrate sequencing with cyto-profiling. This technology allows for the simultaneous examination of DNA, RNA, proteins, phosphoproteins, and cell structure within single cells, offering researchers comprehensive insights into biological systems.

Joshua Sommerfeld, healthcare sector lead at Wellington Management Private Investing, highlighted the unique benefits of Element's platform.

"Their platform combines quality, cost, and flexibility advantages that disrupt the incumbent price curve," he said. "By bringing end-to-end integrated multi-omic workflows onto a single system, Element has the potential to accelerate biological discovery."

Element Biosciences has carved out a notable position within a competitive industry. Jong-Hee (JH) Han, Vice Chairman and CEO of Samsung Electronics, noted the broader impact of Element’s technologies on precision medicine and artificial intelligence.